Compile Data Set for Download or QSAR
Report error Found 27 Enz. Inhib. hit(s) with all data for entry = 10830
TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572022(US11447490, Compound 13)
Affinity DataIC50: 5.10nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572027(US11447490, Compound 17a)
Affinity DataIC50: 6.60nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572034(US11447490, Compound 22)
Affinity DataIC50: 7.40nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572010(BDBM572019 | US11447490, Compound 1)
Affinity DataIC50: 8nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572021(US11447490, Compound 12)
Affinity DataIC50: 8.5nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572012(US11447490, Compound 3)
Affinity DataIC50: 9.20nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572020(US11447490, Compound 11)
Affinity DataIC50: 10nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572018(US11447490, Compound 9)
Affinity DataIC50: 15nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572010(BDBM572019 | US11447490, Compound 1)
Affinity DataIC50: 15nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572013(US11447490, Compound 4)
Affinity DataIC50: 17nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572016(US11447490, Compound 7)
Affinity DataIC50: 21nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572015(US11447490, Compound 6)
Affinity DataIC50: 25nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572024(US11447490, Compound 15)
Affinity DataIC50: 33nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572026(US11447490, Compound 20 | US11447490, Compound 17)
Affinity DataIC50: 34nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572014(US11447490, Compound 5)
Affinity DataIC50: 35nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572011(US11447490, Compound 2)
Affinity DataIC50: 44nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572025(US11447490, Compound 16)
Affinity DataIC50: 48nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572017(US11447490, Compound 8)
Affinity DataIC50: 56nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572032(US11447490, Compound 21)
Affinity DataIC50: 58nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572023(US11447490, Compound 14)
Affinity DataIC50: 78nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572036(US11447490, Comparative compound 24)
Affinity DataIC50: 88nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM476220(US10865384, Compound SB431542 | US11466003, Compou...)
Affinity DataIC50: 108nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572029(US11447490, Compound 19)
Affinity DataIC50: 207nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572028(US11447490, Compound 18)
Affinity DataIC50: 328nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572035(US11447490, Comparative compound 23)
Affinity DataIC50: 372nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572026(US11447490, Compound 20 | US11447490, Compound 17)
Affinity DataIC50: 616nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM572031(US11447490, Compound 21a)
Affinity DataIC50: 4.95E+3nMAssay Description:1. Preparation of a 1× kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Compound preparation: The final detection concentratio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent